European Commission clears Amarin's fish-oil derived heart drug Vazkepa

[March 30, 2021]  (Reuters) - The European Commission has granted Amarin Corporation Plc's fish-oil derived heart drug Vazkepa marketing authorization in the European Union, the drugmaker said on Tuesday.

The authorization allows Amarin to market Vazkepa - sold in the United States as Vascepa - as a treatment to help reduce strokes, heart attacks and other major cardiovascular events in high-risk patients across Europe, the company said.

Vazkepa won U.S. approval in 2012 to lower high triglycerides - a type of blood fat that can increase the risk of heart disease. In December 2019, U.S. health regulators approved expanding the drug's label to include its heart benefit claims.

(Reporting by Vishwadha Chander in Bengaluru; Editing by Rashmi Aich)

© 2021 Thomson Reuters. All rights reserved.]

Copyright 2021 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content